Literature DB >> 26813937

Haematological cancer: Good omens - SIRIUS's glow is auspicious for daratumumab.

David Killock.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26813937     DOI: 10.1038/nrclinonc.2016.9

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

Authors:  Sagar Lonial; Brendan M Weiss; Saad Z Usmani; Seema Singhal; Ajai Chari; Nizar J Bahlis; Andrew Belch; Amrita Krishnan; Robert A Vescio; Maria Victoria Mateos; Amitabha Mazumder; Robert Z Orlowski; Heather J Sutherland; Joan Bladé; Emma C Scott; Albert Oriol; Jesus Berdeja; Mecide Gharibo; Don A Stevens; Richard LeBlanc; Michael Sebag; Natalie Callander; Andrzej Jakubowiak; Darrell White; Javier de la Rubia; Paul G Richardson; Steen Lisby; Huaibao Feng; Clarissa M Uhlar; Imran Khan; Tahamtan Ahmadi; Peter M Voorhees
Journal:  Lancet       Date:  2016-01-07       Impact factor: 79.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.